Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$142.92 USD

142.92
618,051

-0.96 (-0.67%)

Updated Jun 25, 2024 04:00 PM ET

After-Market: $142.90 -0.02 (-0.01%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (37 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Why Is DaVita HealthCare (DVA) Down 9.9% Since Last Earnings Report?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

DaVita (DVA) Earnings and Revenues Miss Estimates in Q1

DaVita (DVA) gains from international revenues in Q1.

DaVita HealthCare (DVA) Q1 Earnings and Revenues Miss Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -4.21% and -2.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for DaVita (DVA) This Earnings Season?

Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to DaVita (DVA) Stock Now

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.

Fresenius Medical's New Hemodialysis Software Gets FDA Nod

Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

DaVita HealthCare (DVA) Down 7.8% Since Last Earnings Report: Can It Rebound?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should Value Investors Consider DaVita (DVA) Stock Now?

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

Here's Why Investors Should Hold DaVita (DVA) Stock Now

DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.

New Strong Sell Stocks for February 19th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Stock Market News For Feb 14, 2019

Wall Street rally continued in Wednesday buoyed by positive developments on the trade war front.

DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates

DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.

DaVita HealthCare (DVA) Tops Q4 Earnings Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 1.12% and -5.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in the Offing for DaVita (DVA) This Earnings Season?

DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) Gains From Sharesource's Global Success Rates

Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.

Baxter's PD Solution to Treat Patients, Prospects Bright

Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.

DaVita HealthCare (DVA) Down 11.9% Since Last Earnings Report: Can It Rebound?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What Falling Estimates & Price Mean for DaVita (DVA)

DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Bright Outlook for Outpatient and Home Healthcare Industry

Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.

DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down

DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.